C10H9BrN2, orthorhombic, P212121 (no. 19), a = 5.9070(3) Å, b = 9.2731(7) Å, c = 17.5641(14) Å, V = 962.09(12) Å3, Z = 4, Rgt(F) = 0.0504, wRref(F2) = 0.0947, T = 293(2) K
C18H17BrN2O2, monoclinic, C2/c (no. 15), a = 23.554(2) Å, b = 9.3060(8) Å, c = 15.7691(15) Å, β = 9...
R factor = 0.043; wR factor = 0.111; data-to-parameter ratio = 17.2. The pyrazole ring in the title ...
C14H10BrClN2O2, orthorhombic, Pca21 (no. 29), a = 32.4137(12) Å, b = 4.6683(2) Å, c = 8.8873(3) Å, V...
C4H2N3BrO4·H2O, monoclinic, P21/c (no. 14), a = 7.177(2) Å, b = 10.999(3) Å, c = 10.414(3) Å, β = 10...
C9H7BrN2O, triclinic, C2/c (no. 15), a = 16.255(3) angstrom, b = 4.4119(9) angstrom, c = 25.923(5) a...
C9H7BrN2O, triclinic, C2/c (no. 15), a = 16.255(3) Å, b = 4.4119(9) Å, c = 25.923(5) Å, β = 107.99(3...
C9H7BrN2O, triclinic, C2/c (no. 15), a = 16.255(3) Å, b = 4.4119(9) Å, c = 25.923(5) Å, β = 107.99(3...
C16H13BrFN3S, monoclinic, P21/c, a = 14.6734(6) Å, b = 11.1226(5) Å, c = 9.4184(4) Å, β = 102.524...
C17H13ClN2O2, monoclinic, P21/c (no. 14), a = 5.3601(4) Å, b = 10.6233(7) Å, c = 25.2125(16) Å, β = ...
C15H14Br2N2O3, triclinic, P1‾$P‾{1}$ (no. 2), a = 7.2748(3) Å, b = 9.0786(4) Å, c = 12.8613(5...
In the title compound, C21H16Br2N2, the central pyrazole ring adopts an flattened envelope conformat...
C14H7Br2N2O2, triclinic, P21/n (no. 14), a = 4.8308(2) Å, b = 6.1438(2) Å, c = 23.0836(9) Å, β = 91....
In the title compound, C21H16Br2N2, the central pyrazole ring adopts an flattened envelope conformat...
C13H8Br2N2OS2, monoclinic, Pc (no. 7), a = 13.4050(4) Å, b = 4.7716(1) Å, c = 11.7303(4) Å, β = 105....
C9H7BrN2O, monoclinic, C2/c (no. 15), a = 16.255(3) angstrom, b = 4.4119(9) angstrom, c = 25.923(5) ...
C18H17BrN2O2, monoclinic, C2/c (no. 15), a = 23.554(2) Å, b = 9.3060(8) Å, c = 15.7691(15) Å, β = 9...
R factor = 0.043; wR factor = 0.111; data-to-parameter ratio = 17.2. The pyrazole ring in the title ...
C14H10BrClN2O2, orthorhombic, Pca21 (no. 29), a = 32.4137(12) Å, b = 4.6683(2) Å, c = 8.8873(3) Å, V...
C4H2N3BrO4·H2O, monoclinic, P21/c (no. 14), a = 7.177(2) Å, b = 10.999(3) Å, c = 10.414(3) Å, β = 10...
C9H7BrN2O, triclinic, C2/c (no. 15), a = 16.255(3) angstrom, b = 4.4119(9) angstrom, c = 25.923(5) a...
C9H7BrN2O, triclinic, C2/c (no. 15), a = 16.255(3) Å, b = 4.4119(9) Å, c = 25.923(5) Å, β = 107.99(3...
C9H7BrN2O, triclinic, C2/c (no. 15), a = 16.255(3) Å, b = 4.4119(9) Å, c = 25.923(5) Å, β = 107.99(3...
C16H13BrFN3S, monoclinic, P21/c, a = 14.6734(6) Å, b = 11.1226(5) Å, c = 9.4184(4) Å, β = 102.524...
C17H13ClN2O2, monoclinic, P21/c (no. 14), a = 5.3601(4) Å, b = 10.6233(7) Å, c = 25.2125(16) Å, β = ...
C15H14Br2N2O3, triclinic, P1‾$P‾{1}$ (no. 2), a = 7.2748(3) Å, b = 9.0786(4) Å, c = 12.8613(5...
In the title compound, C21H16Br2N2, the central pyrazole ring adopts an flattened envelope conformat...
C14H7Br2N2O2, triclinic, P21/n (no. 14), a = 4.8308(2) Å, b = 6.1438(2) Å, c = 23.0836(9) Å, β = 91....
In the title compound, C21H16Br2N2, the central pyrazole ring adopts an flattened envelope conformat...
C13H8Br2N2OS2, monoclinic, Pc (no. 7), a = 13.4050(4) Å, b = 4.7716(1) Å, c = 11.7303(4) Å, β = 105....
C9H7BrN2O, monoclinic, C2/c (no. 15), a = 16.255(3) angstrom, b = 4.4119(9) angstrom, c = 25.923(5) ...
C18H17BrN2O2, monoclinic, C2/c (no. 15), a = 23.554(2) Å, b = 9.3060(8) Å, c = 15.7691(15) Å, β = 9...
R factor = 0.043; wR factor = 0.111; data-to-parameter ratio = 17.2. The pyrazole ring in the title ...
C14H10BrClN2O2, orthorhombic, Pca21 (no. 29), a = 32.4137(12) Å, b = 4.6683(2) Å, c = 8.8873(3) Å, V...
DOI
Add to ORKG